Ascendis Pharma A/S’s (ASND) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report published on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $170.00 price target on the biotechnology company’s stock.

Several other equities analysts have also recently commented on ASND. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $193.43.

Ascendis Pharma A/S Stock Up 13.0 %

Shares of ASND stock opened at $142.49 on Tuesday. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock has a market capitalization of $8.65 billion, a PE ratio of -17.63 and a beta of 0.64. The firm has a 50 day moving average of $132.19 and a two-hundred day moving average of $132.29.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. Analysts expect that Ascendis Pharma A/S will post -7.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the third quarter valued at $30,000. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the period. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth about $60,000. Finally, GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after buying an additional 214 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.